Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence

By Azoulay Laurent  

Breast Cancer Research and Treatment, Vol. 126, Iss. 3, 2011-04 ,pp. : 695-703

Springer Publishing Company

Access to resources Recommend Favorite

Endocrine Therapy for Advanced Breast Cancer: Beyond Tamoxifen and Aromatase Inhibitors

By  

Current Cancer Therapy Reviews, Vol. 6, Iss. 1, 2010-02 ,pp. : 51-61

Bentham Science Publishers

Access to resources Recommend Favorite

Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice

By Ruddy Kathryn   Desantis Stephen   Gelman Rebecca   Wu Alan   Punglia Rinaa   Mayer Erica   Tolaney Sara   Winer Eric   Partridge Ann   Burstein Harold  

Breast Cancer Research and Treatment, Vol. 141, Iss. 3, 2013-10 ,pp. : 421-427

Springer Publishing Company

Access to resources Recommend Favorite

Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen

By Siegelmann-Danieli Nava  

Breast Cancer Research and Treatment, Vol. 125, Iss. 2, 2011-01 ,pp. : 505-510

Springer Publishing Company

Access to resources Recommend Favorite

Aromatase inhibitors reverse tamoxifen induced endometrial ultrasonographic changes in postmenopausal breast cancer patients

By Markovitch O.   Tepper R.   Fishman A.   Aviram R.   Cohen I.  

Breast Cancer Research and Treatment, Vol. 101, Iss. 2, 2007-01 ,pp. : 185-190

Springer Publishing Company

Access to resources Recommend Favorite